Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, primarily in eye care. The company launched XDEMVY (lotilaner ophthalmic solution) in August 2023, the first FDA-approved treatment for Demodex blepharitis. Its pipeline includes TP-04, an investigational sterile aqueous gel formulation of lotilaner for ocular rosacea, and TP-05, an investigational oral tablet formulation for Lyme disease prophylaxis and community malaria reduction. Tarsus serves the U.S. market, targeting patients with Demodex blepharitis, Meibomian Gland Disease, ocular rosacea, and Lyme disease. The company recently announced the acquisition of Alkeus Pharmaceuticals. Its scientific approach targets the root cause of disease, such as Demodex mite infestation, through the inhibition of parasite-specific GABA-Cl channels.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage tarsusrx.com
Sector Healthcare IR page ir.tarsusrx.com
Tags
ophthalmology, demodex blepharitis, ocular rosacea, lyme disease prophylaxis, malaria reduction, lotilaner, gaba-cl channel inhibition, eye care therapeutics, infectious disease prevention, XDEMVY, lotilaner ophthalmic solution, TP-03, TP-04, TP-05, Alkeus Pharmaceuticals
Press page —

Metrics

Valuation  
Market cap $ 3.96B
Market cap (USD) $ 3.96B
P/E -5.30
PEG —
P/BV 38.06
P/S 5.80
P/OCF 79.35
P/FCF 122.05
Dividend yield —
Turnover / mcap —
Returns  
ROE -23.4%
ROI -16.0%
ROIC -12.8%
Profit margin -14.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 70.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 41
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 451.36M 182.953M 17.447M 25.816M 57.027M — —
Net profit -66.418M -115.554M -135.893M -62.091M -13.827M -26.811M -4.67M
Free cash flow -22.31M -84.594M -118.995M -49.536M 3.162M -21.594M -3.848M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 81.88 55.37 20.25 14.66 22.5 41.33 —
Price performance 12m 0.48 1.73 0.38 -0.35 -0.46 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 0.00 0.00 0.00 16.6M 46.8M 85.1M
↳ YoY growth +181.3% +81.9%
Borrowings, non-current (USD) — — — 0.00 19.4M 29.8M 71.8M 72.4M
Lease liabilities (USD) — 164,000 831,000 1.19M 773,000 1.91M 608,000 10.6M
Cash and deposits (USD) 2.38M 58M 168M 171M 71.7M 225M 94.8M 184M
Intangible assets (USD) — — — — 0.00 3.87M 8.33M 7.37M
Right-of-use assets (USD) — 126,000 688,000 1.07M 575,000 1.88M 552,000 10.1M
Net debt (borrowings + leases - cash) (USD) — — — -170M -51.5M -193M -22.4M -101M
Cash flow detail
Operating cash flow (USD) — -3.67M -21.1M 3.75M -49M -117M -83M -12.5M
Purchases of property, plant and equipment (USD) — -175,000 -456,000 -586,000 -506,000 -1.5M -1.57M -9.86M
Purchases of intangible assets (USD) — — — — 0.00 -4M -5M 0.00
Change in receivables (cash effect) (USD) — — — — 0.00 -16.6M -30.1M -38.3M
Change in inventories (cash effect) (USD) — — — — 0.00 -3.11M -2.05M -1.75M
Interest paid (cash effect) (USD) — — — 0.00 -1.68M -2.88M -7.66M -8.34M
Share-based compensation (USD) — 18,000 839,000 8.46M 13.5M 19.8M 27.8M 41.7M
Operating cash flow before change in receivables (USD) — — — — -49M -101M -52.9M 25.8M
Free cash flow (OCF - PPE - intangibles) (USD) — -3.85M -21.6M 3.16M -49.5M -123M -89.6M -22.3M
Income detail
Research and development expense (USD) — 3.16M 18.8M 41.7M 42.6M 50.3M 53.4M 64.3M
↳ 5y CAGR +76.0% +27.9%
Total comprehensive income (USD) — -4.67M -26.8M -13.8M -62.2M -136M -115M -66.2M
Comprehensive income to owners (USD) — -4.67M -26.8M -13.8M -62.2M -136M -115M -66.2M
Reported Nov 25, 2020 Mar 31, 2021 May 11, 2021 Mar 17, 2023 Feb 27, 2024 Feb 27, 2024 Feb 25, 2025 Feb 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Tarsus Reports Third Quarter 2026 Financial Results Bull 5 Bear 5 Results

Generated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year

Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch

Appointed Neera Clase as Chief Commercial Officer

Management to host conference call today, November 3, 2026, at 1:30 p.m. PT / 4:30 p.m. ET

IRVINE, Calif., November 3, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced financial results for the third quarter ended September 30, 2026.

“Ten years ago, we started Tarsus with the conviction that patients with overlooked diseases deserved better,” said Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “XDEMVY has shown what that focus can achieve. In just three years since launch, we have dispensed more than one million bottles and generated $1 billion in cumulative net product sales, and with continued robust growth, we are only getting started. That strength is helping us build one of the most differentiated pipelines in eye care, with the potential to bring five medicines to patients in the next five years.

Oct 28, 2026

PDF Version

IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has served as Tarsus’ Interim Chief Commercial Officer since July 2026 and previously served as Senior Vice President of Market Access.

“Neera has the right experience and vision to lead us into our next chapter of growth,” said Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “She has been instrumental in creating a new market for XDEMVY, building our commercial team and capabilities from the earliest days and securing the broad coverage that has made this launch a standout in eye care. She brings sound judgment, credibility and a deep understanding of our business. As Tarsus expands into retina and advances its broader pipeline, I am confident in Neera’s ability to build on XDEMVY’s success and bring future innovation to more patients.”

As Chief Commercial Officer, Ms. Clase will lead Tarsus’ commercial strategy and execution, with a primary focus on expanding XDEMVY’s reach among eye care professionals and patients. She will also lead commercial planning across one of the most differentiated pipelines in eye care: two Phase 3 retina programs – gildeuretinol (ALK-001), an investigational treatment for Stargardt disease, and IRX-101, an investigational ocular antiseptic; and two Phase 2 programs – TP-04 for ocular rosacea and TP-05 for Lyme disease prevention.

“When I joined Tarsus, we were a small team with a first-in-class medicine and a conviction that we could make a difference for millions of patients living with Demodex blepharitis,” said Ms. Clase. “Helping make XDEMVY accessible to patients has been one of the most rewarding experiences of my career. I believe XDEMVY has the potential to exceed $2 billion in peak sales by reaching more of the patients who need treatment, and delivering on that opportunity is my first priority. As our pipeline advances, I’m excited to engage new communities of physicians and patients and apply what we’ve learned with XDEMVY to the programs ahead.”

Ms. Clase has more than 25 years of biopharmaceutical experience across sales, marketing, market access, reimbursement and commercialization. Previously, she held senior commercial and market access leadership positions at Acadia Pharmaceuticals, Relypsa, Inc., and Abbott Laboratories. She has helped commercialize more than 10 products across multiple therapeutic areas, including several first-in-class therapies. She holds a Bachelor of Arts in life sciences and psychology from Indiana State University and a Master of Social Work from Indiana University.

About XDEMVY**®** XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation. XDEMVY was evaluated in two pivotal trials involving over 800 patients with twice-daily dosing for six weeks. Both trials met the primary endpoint and all secondary endpoints, with statistical significance and no serious treatment-related adverse events. Most patients found the XDEMVY eye drop to be neutral to very comfortable. The most common ocular adverse reactions observed in the studies were instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported by less than 2% of patients were chalazion/hordeolum (stye) and punctate keratitis.

XDEMVY Indication and Important Safety Information

INDICATIONS AND USAGE XDEMVY is indicated for the treatment of Demodex blepharitis.

Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

For additional information, please see full prescribing information available at https://xdemvy.com/.

About Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2, IRX-101 for potential use as an ocular antiseptic, and gildeuretinol for the potential treatment of Stargardt disease.

Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the benefits of the new executive leader, the potential market size of Demodex blepharitis, advancement of Tarsus’ investigational pipeline programs, and the quotations of Tarsus’ management. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Further risks and uncertainties are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus' Form 10-K for the year ended December 31, 2025, filed with the SEC on February 23, 2026, and its most recent Form 10-Q filed with the SEC on August 6, 2026, copies of which are posted on its website and are available from Tarsus without charge. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact: Adrienne Kemp Vice President, Corporate Communications (949) 922-0801 [email protected]

Investor Contact: David Nakasone Head of Investor Relations (949) 620-3223 [email protected]

Sep 29, 2026

PDF Version

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, taking place Sept. 30–Oct. 3 in Anaheim, California.

The planned abstracts provide new insights into the patient burden, diagnosis and treatment of Demodex blepharitis (DB); real-world experiences and outcomes with XDEMVY® (lotilaner ophthalmic solution) 0.25%; and the prevalence and clinical characteristics of ocular rosacea. Together, the findings are expected to add to a growing body of evidence intended to help eye care professionals better recognize and manage diseases that have historically been overlooked or undertreated.

“These 11 abstracts reflect the rapidly evolving understanding of Demodex blepharitis and ocular rosacea—two significant diseases that eye care professionals encounter every day. The findings deepen our understanding of each disease and the impact they can have on patients,” said Elizabeth Yeu, M.D., Chief Medical Officer of Tarsus.

Accepted abstracts include:

Real-World Longitudinal Study of Patients withDemodexBlepharitis and Soft Contact Lens Wear in the United States: Interim Data Analysis (Poster) Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time Location: Anaheim Convention Center (ACC), Exhibit Hall Presenter: Keith Wan, O.D.

Efficacy of Lotilaner 0.25% and Tea Tree Oil inDemodexBlepharitis: A Systematic Review and Meta-analysis (Poster) Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time Location: ACC, Exhibit Hall Presenter: Ian B. Gaddie, O.D.

Retrospective Chart Review ofDemodexBlepharitis Prevalence Among Patients with Chalazia and/or Hordeola (Poster) Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time Location: ACC, Exhibit Hall Presenter: Andrew McLeod, O.D.

Prevalence of Ocular Rosacea in U.S. Eye Care Settings: A Multicenter Retrospective Chart Review (Poster) Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time Location: ACC, Exhibit Hall Presenter: Mile Brujic, O.D.

Assessment of Dry Eye Questionnaires forDemodexBlepharitis: Evidence from a Targeted Literature Review (Poster) Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time Location: ACC, Exhibit Hall Presenter: Walt Whitley, O.D.

Real-World Longitudinal Study of Patients withDemodexBlepharitis in the United States: 9-Month Follow-up Findings (Poster) Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time Location: ACC, Exhibit Hall Presenter: Vanesa Flores, O.D.

Real-World Clinician Re-treatment Practices and Decision Drivers with Lotilaner Ophthalmic Solution, 0.25% forDemodexBlepharitis (Poster) Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time Location: ACC, Exhibit Hall Presenter: Cecelia Koetting, O.D.

Real-World Patient-Reported Satisfaction and Factors Associated with Perceived Benefit of Lotilaner Ophthalmic Solution, 0.25% forDemodexBlepharitis (Poster) Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time Location: ACC, Exhibit Hall Presenter: Jessilin Quint, O.D.

Associations BetweenDemodexInfestation and Meibomian Gland Structure and Function: A Systematic Review (Poster) Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time Location: ACC, Exhibit Hall Presenter: Bridgitte Shen Lee, O.D.

Ocular Bacterial and Fungal Co-infestation inDemodexInfestation: A Systematic Review (Poster) Date: Thursday, October 1, 2026, 4:30 – 6:30PM Pacific Daylight Time Location: ACC, Exhibit Hall Presenter: Pamela Theriot, O.D.

Assessment of Tea Tree-Based Management inDemodexBlepharitis: A Real-World Longitudinal Study (Paper) Date: Friday, October 2, 2026, 4:00 – 4:15PM Pacific Daylight Time Location: ACC, Room 255 C Presenter: Selina McGee, O.D.

AboutDemodexBlepharitis Blepharitis is a common lid margin disease that is characterized by eyelid margin inflammation, redness and ocular irritation. Demodex blepharitis is caused by an infestation of Demodex mites, the most common ectoparasites found on humans, and accounts for over two-thirds of all blepharitis cases. Demodex blepharitis may affect as many as 25 million Americans based on an extrapolation from the Titan study indicating 58% of patients presenting to U.S. eye care clinics have collarettes, a pathognomonic sign of Demodex mite infestation, and that at least 45 million people annually visit an eye care clinic. Demodex blepharitis can have a significant clinical burden and negative impact on patients’ daily lives.

About XDEMVY**®** XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation. XDEMVY was evaluated in two pivotal trials involving over 800 patients with twice-daily dosing for six weeks. Both trials met the primary endpoint and all secondary endpoints, with statistical significance and no serious treatment-related adverse events. Most patients found the XDEMVY eye drop to be neutral to very comfortable. The most common ocular adverse reactions observed in the studies were instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported by less than 2% of patients were chalazion/hordeolum (stye) and punctate keratitis.

XDEMVY Indication and Important Safety Information

Indications and Usage XDEMVY (lotilaner ophthalmic solution) 0.25% is indicated for the treatment of Demodex blepharitis.

Important Safety Information **Most common side effects:**The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.

**Handling the Container:**Avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to minimize contamination of the solution. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

**When to Seek Physician Advice:**Immediately seek a physician’s advice concerning the continued use of XDEMVY if you develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions.

**Use with Contact Lenses:**XDEMVY contains potassium sorbate, which may discolor soft contact lenses. Contact lenses should be removed prior to instillation of XDEMVY and may be reinserted 15 minutes following its administration.

To report SUSPECTED ADVERSE REACTIONS, contact Tarsus Pharmaceuticals at 1-888-421-4002 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional information please see Full Prescribing Information available at: www.xdemvy.com.

About Ocular Rosacea Ocular rosacea is a prevalent, undertreated inflammatory disease affecting the eyes, eyelids and surrounding tissue. The condition may be associated with redness of the eyes and eyelids, prominent blood vessels, irritation and other ocular symptoms. Ocular rosacea is estimated to affect 15–18 million people in the United States, and there are currently no FDA-approved therapies specifically indicated for the disease.

About Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2, IRX-101 for potential use as an ocular antiseptic, and gildeuretinol for the potential treatment of Stargardt disease.

Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the timing, content, location, and presenters of scientific abstracts at an upcoming medical conference, our ability to continue to educate the market and generate data about Demodex blepharitis, the potential market size of Demodex blepharitis globally, and the quotations of Tarsus’ management. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Further risks and uncertainties are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus' Form 10-K for the year ended December 31, 2025 filed with the SEC on February 23, 2026, and its most recent Form 10-Q filed with the SEC on August 6, 2026, copies of which are posted on its website and are available from Tarsus without charge. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact: Adrienne Kemp Vice President, Corporate Communications (949) 922-0801 [email protected]

Investor Contact: David Nakasone Head of Investor Relations (949) 620-3223 [email protected]

Prompts

Tarsus Pharmaceuticals, Inc. (ticker TARS), listed in United States.

ETFs Holding Tarsus Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
MMSC 0.31% 1,942 $ 152.797K Nov 16, 2026
FSEG 0.27% 248 $ 15.609K Jun 30, 2026
HELX 0.26% 1,136 $ 71.5K Jun 30, 2026
RUSC 0.16% 2,014 $ 126.761K Jun 30, 2026
ESSC 0.16% 952 $ 56.206K Jul 31, 2026
SEIS 0.13% 12,214 $ 768.749K Jun 30, 2026
RESM 0.12% 69 $ 4,342.86 Jun 30, 2026
FSML 0.07% 1,459 $ 91.829K Jun 30, 2026
MSSM 0.02% 1,500 $ 111.36K Aug 31, 2026
FESM 0.00% 42 $ 2,643.48 Jun 30, 2026